Pricing

Cardiff Oncology Inc (CRDF)

followers ·
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Mark Erlander
Employees:
20
11055 FLINTKOTE AVENUE, SAN DIEGO, CA, 92121
858-952-7570
Stock Split History
DateRatio
2004-07-27 111:1
2012-05-30 1:6
2018-06-04 1:12
2019-02-20 1:6
Cardiff Oncology, Inc. develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available